Utilization patterns for oral oncology medications in a specialty pharmacy cycle management program.
Identifieur interne : 000115 ( Main/Exploration ); précédent : 000114; suivant : 000116Utilization patterns for oral oncology medications in a specialty pharmacy cycle management program.
Auteurs : Sarah Deutsch [Oman] ; Pamela Koerner [États-Unis] ; Richard T. Miller [États-Unis] ; Zoie Craft [États-Unis] ; Karen Fancher [États-Unis]Source :
- Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [ 1477-092X ] ; 2016.
Descripteurs français
- KwdFr :
- MESH :
- traitement médicamenteux : Tumeurs.
- usage thérapeutique : Antinéoplasiques.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Jeune adulte, Mâle, Pharmacie, Pharmaciens, Services pharmaceutiques, Sujet âgé, Sujet âgé de 80 ans ou plus, Études rétrospectives.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antineoplastic Agents.
- drug therapy : Neoplasms.
- methods : Pharmacy.
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Pharmaceutical Services, Pharmacists, Retrospective Studies, Young Adult.
Abstract
The cycle management program (CMP) was implemented in 2008 at a national specialty pharmacy with a focus on providing specialized counseling and monitoring for patients on select oral oncology medications. The program now includes nine medications: bexarotene, dasatinib, erlotinib, everolimus, nilotinib, pazopanib, sorafenib, sunitinib, and vorinostat. Patients receive frequent assessments to encourage adherence, identify adverse events, and track discontinuations through a pharmacist outreach at the initiation of therapy, day 10 and 20 of the first month, then monthly thereafter. The use of oral agents is increasing in cancer patients, shifting away from regimens exclusively involving intravenous chemotherapy. This offers advantages for patients in terms of convenience, but introduces risk as patients become more responsible for the administration and monitoring of the medications.
DOI: 10.1177/1078155214547664
PubMed: 25301744
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000040
- to stream PubMed, to step Curation: 000040
- to stream PubMed, to step Checkpoint: 000040
- to stream Ncbi, to step Merge: 003962
- to stream Ncbi, to step Curation: 003962
- to stream Ncbi, to step Checkpoint: 003962
- to stream Main, to step Merge: 000115
- to stream Main, to step Curation: 000115
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Utilization patterns for oral oncology medications in a specialty pharmacy cycle management program.</title><author><name sortKey="Deutsch, Sarah" sort="Deutsch, Sarah" uniqKey="Deutsch S" first="Sarah" last="Deutsch">Sarah Deutsch</name><affiliation wicri:level="1"><nlm:affiliation>Walgreens Specialty Pharmacy, Carnegie, PA, USA sarah.deutsch@walgreens.com.</nlm:affiliation><country wicri:rule="url">Oman</country><wicri:regionArea>Walgreens Specialty Pharmacy, Carnegie, PA</wicri:regionArea><wicri:noRegion>PA</wicri:noRegion></affiliation></author><author><name sortKey="Koerner, Pamela" sort="Koerner, Pamela" uniqKey="Koerner P" first="Pamela" last="Koerner">Pamela Koerner</name><affiliation wicri:level="2"><nlm:affiliation>Duquesne University Mylan School of Pharmacy, Pittsburgh, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Duquesne University Mylan School of Pharmacy, Pittsburgh, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Miller, Richard T" sort="Miller, Richard T" uniqKey="Miller R" first="Richard T" last="Miller">Richard T. Miller</name><affiliation wicri:level="2"><nlm:affiliation>Walgreens Specialty Pharmacy, Carnegie, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Walgreens Specialty Pharmacy, Carnegie, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Craft, Zoie" sort="Craft, Zoie" uniqKey="Craft Z" first="Zoie" last="Craft">Zoie Craft</name><affiliation wicri:level="2"><nlm:affiliation>Walgreens Specialty Pharmacy, Carnegie, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Walgreens Specialty Pharmacy, Carnegie, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Fancher, Karen" sort="Fancher, Karen" uniqKey="Fancher K" first="Karen" last="Fancher">Karen Fancher</name><affiliation wicri:level="2"><nlm:affiliation>Duquesne University Mylan School of Pharmacy, Pittsburgh, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Duquesne University Mylan School of Pharmacy, Pittsburgh, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:25301744</idno><idno type="pmid">25301744</idno><idno type="doi">10.1177/1078155214547664</idno><idno type="wicri:Area/PubMed/Corpus">000040</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000040</idno><idno type="wicri:Area/PubMed/Curation">000040</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000040</idno><idno type="wicri:Area/PubMed/Checkpoint">000040</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000040</idno><idno type="wicri:Area/Ncbi/Merge">003962</idno><idno type="wicri:Area/Ncbi/Curation">003962</idno><idno type="wicri:Area/Ncbi/Checkpoint">003962</idno><idno type="wicri:Area/Main/Merge">000115</idno><idno type="wicri:Area/Main/Curation">000115</idno><idno type="wicri:Area/Main/Exploration">000115</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Utilization patterns for oral oncology medications in a specialty pharmacy cycle management program.</title><author><name sortKey="Deutsch, Sarah" sort="Deutsch, Sarah" uniqKey="Deutsch S" first="Sarah" last="Deutsch">Sarah Deutsch</name><affiliation wicri:level="1"><nlm:affiliation>Walgreens Specialty Pharmacy, Carnegie, PA, USA sarah.deutsch@walgreens.com.</nlm:affiliation><country wicri:rule="url">Oman</country><wicri:regionArea>Walgreens Specialty Pharmacy, Carnegie, PA</wicri:regionArea><wicri:noRegion>PA</wicri:noRegion></affiliation></author><author><name sortKey="Koerner, Pamela" sort="Koerner, Pamela" uniqKey="Koerner P" first="Pamela" last="Koerner">Pamela Koerner</name><affiliation wicri:level="2"><nlm:affiliation>Duquesne University Mylan School of Pharmacy, Pittsburgh, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Duquesne University Mylan School of Pharmacy, Pittsburgh, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Miller, Richard T" sort="Miller, Richard T" uniqKey="Miller R" first="Richard T" last="Miller">Richard T. Miller</name><affiliation wicri:level="2"><nlm:affiliation>Walgreens Specialty Pharmacy, Carnegie, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Walgreens Specialty Pharmacy, Carnegie, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Craft, Zoie" sort="Craft, Zoie" uniqKey="Craft Z" first="Zoie" last="Craft">Zoie Craft</name><affiliation wicri:level="2"><nlm:affiliation>Walgreens Specialty Pharmacy, Carnegie, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Walgreens Specialty Pharmacy, Carnegie, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Fancher, Karen" sort="Fancher, Karen" uniqKey="Fancher K" first="Karen" last="Fancher">Karen Fancher</name><affiliation wicri:level="2"><nlm:affiliation>Duquesne University Mylan School of Pharmacy, Pittsburgh, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Duquesne University Mylan School of Pharmacy, Pittsburgh, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author></analytic><series><title level="j">Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners</title><idno type="eISSN">1477-092X</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antineoplastic Agents (therapeutic use)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neoplasms (drug therapy)</term><term>Pharmaceutical Services</term><term>Pharmacists</term><term>Pharmacy (methods)</term><term>Retrospective Studies</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antinéoplasiques (usage thérapeutique)</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Pharmacie ()</term><term>Pharmaciens</term><term>Services pharmaceutiques</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Tumeurs (traitement médicamenteux)</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Pharmacy</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pharmaceutical Services</term><term>Pharmacists</term><term>Retrospective Studies</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Pharmacie</term><term>Pharmaciens</term><term>Services pharmaceutiques</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The cycle management program (CMP) was implemented in 2008 at a national specialty pharmacy with a focus on providing specialized counseling and monitoring for patients on select oral oncology medications. The program now includes nine medications: bexarotene, dasatinib, erlotinib, everolimus, nilotinib, pazopanib, sorafenib, sunitinib, and vorinostat. Patients receive frequent assessments to encourage adherence, identify adverse events, and track discontinuations through a pharmacist outreach at the initiation of therapy, day 10 and 20 of the first month, then monthly thereafter. The use of oral agents is increasing in cancer patients, shifting away from regimens exclusively involving intravenous chemotherapy. This offers advantages for patients in terms of convenience, but introduces risk as patients become more responsible for the administration and monitoring of the medications.</div></front></TEI><affiliations><list><country><li>Oman</li><li>États-Unis</li></country><region><li>Pennsylvanie</li></region></list><tree><country name="Oman"><noRegion><name sortKey="Deutsch, Sarah" sort="Deutsch, Sarah" uniqKey="Deutsch S" first="Sarah" last="Deutsch">Sarah Deutsch</name></noRegion></country><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Koerner, Pamela" sort="Koerner, Pamela" uniqKey="Koerner P" first="Pamela" last="Koerner">Pamela Koerner</name></region><name sortKey="Craft, Zoie" sort="Craft, Zoie" uniqKey="Craft Z" first="Zoie" last="Craft">Zoie Craft</name><name sortKey="Fancher, Karen" sort="Fancher, Karen" uniqKey="Fancher K" first="Karen" last="Fancher">Karen Fancher</name><name sortKey="Miller, Richard T" sort="Miller, Richard T" uniqKey="Miller R" first="Richard T" last="Miller">Richard T. Miller</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000115 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000115 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25301744
|texte= Utilization patterns for oral oncology medications in a specialty pharmacy cycle management program.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25301744" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PittsburghV1
| This area was generated with Dilib version V0.6.38. |  |